Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real Life Clinical Practice, Multicenter Study Of Ixazomib Based First Line Therapy Comparing Efficacy And Safety Profile With Reported Data In Randomised Clinical Trials In China

Next Previous
Trial Profile

Real Life Clinical Practice, Multicenter Study Of Ixazomib Based First Line Therapy Comparing Efficacy And Safety Profile With Reported Data In Randomised Clinical Trials In China

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Lenalidomide; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 01 Nov 2020 Results published in the Annals of Hematology
  • 12 Dec 2019 New trial record
  • 10 Dec 2019 Results (n=60), Comparing efficacy and safety of Ixazomib as a first line therapy data with already reported data from randomized clinical trial in Chinese patients with newly diagnosed Multiple Myeloma, presented at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top